ストックスクリーナーアプリを入手
2.70
1.46%
-0.04
前日終値:
$2.74
開ける：
$2.75
24時間の取引高:
12,300
Relative Volume:
0.32
時価総額：
$1.48M
収益：
当期純損益:
$-13.47M
株価収益率:
-0.0694
EPS:
-38.9215
ネットキャッシュフロー:
$-8.38M
1週間 パフォーマンス:
-17.18%
1か月 パフォーマンス:
-28.00%
6か月 パフォーマンス:
-93.83%
1年 パフォーマンス:
-97.51%
1日の値動き範囲:
$2.70
$2.7594
1週間の範囲:
$2.70
$3.25
52週間の値動き範囲:
$2.70
$179.19
Artelo Biosciences Inc Stock (ARTL) Company Profile
名前
Artelo Biosciences Inc
セクター
電話
858-925-7049
住所
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
2.70 | 1.48M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-02-12 | 開始されました | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc (ARTL) 最新ニュース
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket - Benzinga
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com South Africa
Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com Canada
Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com UK
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - ca.finance.yahoo.com
Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us
Artelo Biosciences Inc. Warrant (ARTLW) Peer Comparison – Compare with Others - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Artelo Biosciences Inc. Warrant (ARTLW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Artelo Biosciences Inc (NASDAQ: ARTL) Share Price, ARTL Stock News, ARTL Share Price & Updates - kalkine.ca
Artelo Biosciences Inc. (ARTL) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Artelo Biosciences To Carry Out 1-for-9 Reverse Stock Split On August 31st, 2026 - Moomoo
Artelo Biosciences Inc. (ARTL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com India
Artelo Biosciences (Nasdaq: ARTL) to trade post-split Aug 31 - Stock Titan
Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com
Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com Canada
Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com UK
Artelo Biosciences Announces Reverse Stock Split - Barchart.com
Artelo Biosciences Announces Reverse Stock Split - finance.yahoo.com
Artelo Biosciences will combine every 9 shares into 1 starting Aug. 31 - Stock Titan
Artelo (ARTL) Technicals: Declines 2.86% to $0.69 at the Close; Range View - vinanet.vn
Armistice Capital Exits Artelo Biosciences (ARTL) Position in Co - GuruFocus
Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation - Bitget
Artelo Biosciences (ARTL) Secures Japanese Patent for ART27.13, Extending IP Protection to 2041 - GuruFocus
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - The Manila Times
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Yahoo Finance
Artelo (ARTL) Results at a Glance: The Latest Report Adds New Financial Reference Points at the Close; Share Response: Shares Move 1.25% Up in the Latest ReadingEarnings Preview - vinanet.vn
Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Geographic Revenue Trends - dars.gov.et
Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Earnings Analysis - vinanet.vn
Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus
Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies - Yahoo Finance
ARTL Q2 2026 Earnings: Reported EPS of -$0.89 Reflects Continued Development FocusROIC Trend Report - vinanet.vn
Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade
Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade
ARTL Q2 2026 Earnings: Reported Loss of -$0.89 Per Share Highlights Clinical-Stage InvestmentGuidance vs Actual - vinanet.vn
Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan
Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com
Artelo Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade
Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan
Artelo Biosciences Q2 Net Income USD -2.4 Mil - Moomoo
Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain - Stock Titan
Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan
Artelo Biosciences (ARTL) Advances 6.34% to $0.75 as Micro-Cap Biotech Tests Key ResistanceDebt Free Companies - vinanet.vn
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo Biosciences Inc (ARTL) 財務データ
収益
当期純利益
現金流量
EPS
4.22%
大文字化:
|
ボリューム (24 時間):